Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort

Solid papillary breast carcinoma resembling the tall cell variant of papillary thyroid neoplasms (BPTC), also known as solid papillary carcinoma with reverse polarity, is a rare histological type of breast cancer that resembles morphologically the tall cell variant of papillary thyroid carcinoma. BPTCs are characterised by IDH2 R172 hotspot somatic mutations or mutually exclusive TET2 somatic mutations, concurrently with mutations affecting PI3K pathway‐related genes. We sought to characterise their histology and investigate the frequency of IDH2 and PIK3CA mutations in an independent cohort of BPTCs, as well as in conventional solid papillary carcinomas (SPCs).

[1]  Melissa P. Murray,et al.  Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis‐generating study , 2017, Histopathology.

[2]  I. Ellis,et al.  Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms: A Unique Invasive Tumor With Indolent Behavior , 2017, The American journal of surgical pathology.

[3]  M. Nikiforova,et al.  Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma: A Solid Papillary Neoplasm With Characteristic Immunohistochemical Profile and Few Recurrent Mutations , 2017, American journal of clinical pathology.

[4]  Julie M. Batten,et al.  IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. , 2016, Cancer research.

[5]  I. Ellis,et al.  Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile , 2016, Histopathology.

[6]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[7]  I. Ellis,et al.  Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring TP53 somatic mutations , 2016, The Journal of pathology.

[8]  K. Yen,et al.  IDH mutations in cancer and progress toward development of targeted therapeutics. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Ladanyi,et al.  Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression , 2016, The Journal of pathology.

[10]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[11]  M. Giansanti,et al.  An Additional Case of Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma , 2015, International journal of surgical pathology.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[13]  Hui Yang,et al.  IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[15]  Y. Xiong,et al.  The mechanisms of IDH mutations in tumorigenesis , 2012, Cell Research.

[16]  S. Masood,et al.  Changing the Term “Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma” to “Tall Cell Variant of Papillary Breast Carcinoma” , 2012, Advances in anatomic pathology.

[17]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[18]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[19]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[20]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[21]  J. Pfeifer,et al.  Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma , 2009, Modern Pathology.

[22]  I. Abdulkader,et al.  Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: A Case Report , 2006, International journal of surgical pathology.

[23]  I. Ellis,et al.  Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: Report of 5 Cases , 2003, The American journal of surgical pathology.